# Personalis (NeXT Personal)
> Personalis is a cancer genomics company that provides advanced genomic sequencing and analytics for precision medicine. Its flagship NeXT Platform, particularly NeXT Personal, is designed to detect minimal residual disease (MRD) with ultra-high sensitivity by identifying a personalized signature of up to 1,800 mutations in a patient's tumor.
- URL: https://optimly.ai/brand/personalis-next-personal
- Slug: personalis-next-personal
- BAI Score: 72/100
- Archetype: Challenger
- Category: Biotechnology
- Last Analyzed: April 10, 2026
## Competitors
- Adaptive Biotechnologies (https://optimly.ai/brand/adaptive-biotechnologies)
- Foundation Medicine (https://optimly.ai/brand/foundation-medicine)
- Natera (Signatera) (https://optimly.ai/brand/natera-signatera)
## Buyer Intent Signals
Problems: Standard Pathology Monitoring: Hospital pathology departments manually performing tissue staining and analysis without personalized longitudinal monitoring. | Clinical Research Agencies: Hiring specialized clinical research organizations to manage patient monitoring data manually.
Solutions: ultra-sensitive MRD testing oncology | tumor-informed liquid biopsy companies | whole genome cancer recurrence monitoring | NeXT personal clinical trial results | best test for early cancer recurrence detection | Adjacent Screening Tools: Utilizing liquid biopsy tools designed for early detection (e.g., GRAIL) rather than post-diagnosis recurrence monitoring.
---
## Full Details / RAG Data
### Overview
Personalis (NeXT Personal) is listed in the AI Directory.
Personalis is a cancer genomics company that provides advanced genomic sequencing and analytics for precision medicine. Its flagship NeXT Platform, particularly NeXT Personal, is designed to detect minimal residual disease (MRD) with ultra-high sensitivity by identifying a personalized signature of up to 1,800 mutations in a patient's tumor.
### Metadata
| Field        | Value |
|--------------|-------|
| Name         | Personalis (NeXT Personal) |
| Slug         | personalis-next-personal |
| URL          | https://optimly.ai/brand/personalis-next-personal |
| BAI Score    | 72/100 |
| Archetype    | Challenger |
| Category     | Biotechnology |
| Last Analyzed | April 10, 2026 |
| Last Updated | 2026-05-05T01:26:39.905Z |
### Verified Facts
- Founded: 2011
- Headquarters: Menlo Park, California
### Competitors
| Name | Profile |
|------|---------|
| Adaptive Biotechnologies | https://optimly.ai/brand/adaptive-biotechnologies |
| Foundation Medicine | https://optimly.ai/brand/foundation-medicine |
| Natera (Signatera) | https://optimly.ai/brand/natera-signatera |
### Buyer Intent Signals
#### Problems this brand solves
- Standard Pathology Monitoring: Hospital pathology departments manually performing tissue staining and analysis without personalized longitudinal monitoring.
- Clinical Research Agencies: Hiring specialized clinical research organizations to manage patient monitoring data manually.
#### Buyers search for
- ultra-sensitive MRD testing oncology
- tumor-informed liquid biopsy companies
- whole genome cancer recurrence monitoring
- NeXT personal clinical trial results
- best test for early cancer recurrence detection
- Adjacent Screening Tools: Utilizing liquid biopsy tools designed for early detection (e.g., GRAIL) rather than post-diagnosis recurrence monitoring.
### Links
- Canonical page: https://optimly.ai/brand/personalis-next-personal
- JSON endpoint: /brand/personalis-next-personal.json
- LLMs.txt: /brand/personalis-next-personal/llms.txt